Hanny Al-Samkari
Hematologist and clinical investigator at Massachusetts General Hospital with expertise in immune thrombocytopenia and emerging therapies discussed at ASH.
Top 3 podcasts with Hanny Al-Samkari
Ranked by the Snipd community
9 snips
Mar 9, 2026 • 19min
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari, hematologist and clinical investigator at Massachusetts General Hospital, discusses ASH 2025 trial data on BTK inhibitors and BAFF-R antagonists. He reviews VEHIT and YAHIT trial designs, durable response rates, and differences between yonalimab and rituximab. Other highlights include fatigue mechanisms, surgery guidance for rilzabrutinib, and impacts on chemotherapy-induced thrombocytopenia.
Mar 21, 2026 • 29min
Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari, a hematologist and clinical investigator at Massachusetts General Hospital, discusses ASH 2025 advances in immune thrombocytopenia. He covers combining TPO receptor agonists with B-cell therapies, emergency rescue strategies including splenectomy, choices to avoid thrombocytosis, and practical concerns like iron deficiency and steroid strategies.
Mar 3, 2026 • 24min
Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari, hematologist and clinical investigator at Massachusetts General Hospital, discusses novel ITP therapies from ASH 2025. He explains yonalimab’s BAFF-R mechanism, dosing, safety and effects on infections and allergies. He also covers rilzabrutinib’s BTK selectivity, LUNA-3 results, dosing challenges, and how these agents might be sequenced in practice.
